Philadelphia, PA—When preparing to tackle oncology drug reimbursement concerns, it is critical to understand the benchmarks that influence reimbursement, according to John F. Aforismo, BScPharm, RPh, FASCP, Chief Executive Officer, RJ Health Systems Inter – national, Rocky Hill, CT. At [ Read More ]
Economics & Value
Philadelphia, PA—Changes in oncology reimbursement have driven the consolidation of community oncology practices, as more of these practices are being squeezed financially, according to Ted Okon, BS, MBA, Executive Director, Community Oncology Alliance. Consoli dation decreases alternatives, and that means reduced competition, as many oncologists lose their practices.
[ Read More ]
Philadelphia, PA—Third-party oncology benefits management, tiered networks, and accountable care organizations (ACOs) are some of the trends gaining traction in the health insurance industry, according to Donald Liss, MD, Senior Medical Director, Independence Blue Cross of Philadelphia, who described cancer care from a large insurer’s perspective.
[ Read More ]
US and Canadian medical oncologists share similar attitudes on the costs, cost-effectiveness, and health policies concerning new cancer drugs, despite fundamental differences between the 2 countries regarding how these drugs are covered and paid for under their respective healthcare systems. [ Read More ]
An interview with Brian Sweet, RPh, MBA In May 2010, the health benefits company WellPoint, Inc, announced a policy of using comparative effectiveness research (CER) as part of the firm’s formulary decision-making process. This is not surprising given the emphasis [ Read More ]
Researchers from the University of California and the University of California San Diego (UCSD) have begun working on a prototype “cyberinfrastructure” that would allow cancer researchers to collect and interpret data from multiple sources to compare the effectiveness of preventive [ Read More ]
Due to changes in the US Food and Drug Administration (FDA) approval process for cancer drugs, many new cancer drugs have been approved over the past 10 to 15 years. Although the availability of these new drugs has improved survival for many cancer patients, there is increasing concern [ Read More ]